| Are Losartan and Imatinib Effective Against SARS-CoV2 Pthogenesis? A Pathophysiology-Based in Silico Study R Nejat, AS Sadr In Silico Pharmacology 9 (1), 1, 2020 | 38 | 2020 |
| Losartan Inhibits SARS-CoV-2 Replication in vitro: Losartan promotes cell survival following SARS-CoV-2 infection in vitro R Nejat, AS Sadr, B Freitas, J Crabttree, SD Pegan, RA Tripp, D Najafi Journal of Pharmacy & Pharmaceutical Sciences 24, 390-399, 2021 | 17 | 2021 |
| Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013 A Ahmadi, SH Ardehali, MT Beigmohammadi, M Hajiabdolbaghi, ... JRSM open 5 (3), 2042533313517689, 2014 | 17 | 2014 |
| S protein, ACE2 and host cell proteases in SARS-CoV-2 cell entry and infectivity; is soluble ACE2 a two blade sword? A narrative review R Nejat, MF Torshizi, DJ Najafi Vaccines 11 (2), 204, 2023 | 10 | 2023 |
| SARS Virus Papain-like Protease: A Mysterious Weapon R Nejat, AS Sadr Journal of Biostatistics and Epidemiology 5 (4), 321-328, 2019 | 7 | 2019 |
| Neuro-protective effect of Erythropoietin R Nejat World Brain Congress, Dec 5-7, 2018, Dubai, UAE, 2018 | 3 | 2018 |
| Atherosclerosis and Platelets R Nejat http://rezanejat.com/2017/03/29/%d8%a2%d8%aa%d8%b1%d9%88%d8%a7%d8%b3%da%a9 …, 2005 | 3* | 2005 |
| Erythropoietin and Neuroinflammation R Nejat 11th World Congress on Neuropharmacology, May 6-7, 2019 Prague, Czech …, 2019 | 2 | 2019 |
| GPCRs of diverse physiologic and pathologic effects with fingerprints in COVID-19 R Nejat, AS Sadr, MF Torshizi, DJ Najafi Biology and Life Sciences Forum 7 (1), 19, 2021 | 1 | 2021 |
| Losartan promotes cell survival following SARS-CoV-2 infection in vitro R Nejat, AS Sadr, BT Freitas, J Crabtree, SD Pegan, RA Tripp, DJ Najafi bioRxiv, 2020.12. 27.424507, 2020 | 1 | 2020 |
| Erythropoietin in COVID-19-Induced Neuroinflammation; EPO Plus Losartan Might be Promising R Nejat, AS Sadr, D Najafi Journal of Biostatistics and Epidemiology, 2020 | 1 | 2020 |
| Daily Low Dose of Erythropoietin in Neuroinflammation; EPO Might Be Hazardous in COVID-19 R Nejat, AS Sadr, A Ebrahimi, A Nabati, E Eshaghi | 1 | 2020 |
| Daily Low Dose of Erythropoietin and Neuroinflammation R Nejat, AS Sadr, A Ebrahimi, A Nabati, E Eshaghi preprint, 2020 | 1 | 2020 |
| S protein, ACE2 and Host Cell Proteases in SARS-CoV2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword?(preprint) R Nejat, MF Torshizi, DJ Najafi | | 2022 |
| GPCRs of diverse physiologic and pathologic effects with their fingerprints in COVID-19 R Nejat, AS Sadr, D Najafi MDPI, 2021 | | 2021 |
| GPCRs of Diverse Physiologic and Pathologic Effects with Fingerprints in COVID-19 (preprint) R Nejat, AS Sadr, DJ Najafi | | 2021 |
| Losartan might be effective in attenuating ARDS in COVID 19 R Nejat https://youtu.be/kpyDrxw1kAI, 2020 | | 2020 |
| A Review of COVID19 R Nejat https://youtu.be/yW1q5ipqk6k, 2020 | | 2020 |
| Are Losartan and Imatinib Effective Against SARS-CoV2 Pathogenesis? a Pathophysiologic-Based in Silico Study (preprint) R Nejat, AS Sadr | | 2020 |
| Losartan promotes cell survival following SARS-CoV-2 infection in vitro (preprint) R Nejat, AS Sadr, BT Freitas, J Crabtree, SD Pegan, RA Tripp, DJ Najafi, ... | | 2020 |
